Core Viewpoint - Jiach Technology's stock price has shown fluctuations, with a current price of 65.01 CNY per share, reflecting a year-to-date increase of 6.75% but a decline over the past 60 days of 13.45% [1] Financial Performance - For the period from January to September 2025, Jiach Technology reported a revenue of 619 million CNY, representing a year-on-year growth of 5.21%. However, the net profit attributable to shareholders decreased by 22.39% to 249 million CNY [2] - The company has distributed a total of 160 million CNY in dividends since its A-share listing [3] Shareholder Structure - As of September 30, 2025, the number of shareholders decreased by 40.76% to 5,446, while the average number of circulating shares per person increased by 68.80% to 7,052 shares [2] - The top circulating shareholders include several new entrants, with the largest being Southern Military Reform Flexible Allocation Mixed A, holding 2.1658 million shares [3]

Core Viewpoint - Zhongji United experienced a stock price decline of 2.09% on November 19, with a current price of 41.22 CNY per share and a total market capitalization of 8.76 billion CNY [1] Financial Performance - For the period from January to September 2025, Zhongji United reported a revenue of 1.352 billion CNY, representing a year-on-year growth of 44.75%, and a net profit attributable to shareholders of 438 million CNY, which is an increase of 83.99% compared to the previous year [2] - The company has distributed a total of 409 million CNY in dividends since its A-share listing, with 284 million CNY distributed over the last three years [3] Shareholder Information - As of November 10, Zhongji United had 25,000 shareholders, an increase of 13.76% from the previous period, with an average of 8,503 circulating shares per shareholder, down by 12.10% [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited as the third-largest shareholder with 6.5225 million shares, an increase of 3.3557 million shares from the previous period [3] Stock Market Activity - Zhongji United's stock has increased by 49.84% year-to-date, but has seen a decline of 6.36% over the last five trading days [1] - The company has appeared on the "Dragon and Tiger List" once this year, with the most recent occurrence on July 16 [1] Business Overview - Zhongji United, established on July 21, 2005, and listed on May 6, 2021, specializes in the research, production, and sale of specialized high-altitude safety operation equipment, with a revenue composition of 66.87% from high-altitude safety lifting equipment, 29.29% from safety protection equipment, and 3.21% from safety operation services [1]

Core Viewpoint - Garden Biologics' stock has shown fluctuations with a recent increase of 2.14%, reflecting a total market capitalization of 7.788 billion yuan, while the company continues to focus on developing a complete vitamin D3 industry chain [1] Financial Performance - For the period from January to September 2025, Garden Biologics reported a revenue of 936 million yuan, a slight decrease of 0.20% year-on-year, and a net profit attributable to shareholders of 234 million yuan, down 3.07% year-on-year [2] - Cumulative cash dividends since the company's A-share listing amount to 446 million yuan, with 178 million yuan distributed over the past three years [3] Shareholder Information - As of November 10, 2025, the number of shareholders for Garden Biologics reached 29,100, an increase of 2.11% from the previous period, while the average circulating shares per person decreased by 2.06% to 18,378 shares [2] - The top ten circulating shareholders include Southern CSI 1000 ETF, holding 3.4785 million shares, which decreased by 48,400 shares compared to the previous period [3] Stock Performance - Year-to-date, Garden Biologics' stock price has decreased by 1.48%, but it has seen a 1.70% increase over the last five trading days and a 6.62% increase over the last twenty days [1]

Group 1 - The core viewpoint of the news is that Aipeng Medical's stock has experienced significant fluctuations, with a year-to-date increase of 51.84% but a recent decline of 13.16% over the past five trading days [2] - As of November 19, Aipeng Medical's stock price was 26.67 yuan per share, with a market capitalization of 3.362 billion yuan [1] - The company has seen a net outflow of main funds amounting to 639.98 million yuan, with large orders accounting for 11.36% of total buying and 22.68% of total selling [1] Group 2 - Aipeng Medical's main business revenue composition includes 59.73% from pain management products, 29.40% from nasal and upper airway products, and 10.87% from other sources [2] - The company has been listed on the stock market since December 13, 2018, and is located in Rudong County, Jiangsu Province [2] - As of September 30, the number of shareholders decreased by 31.76% to 22,100, while the average circulating shares per person increased by 46.51% to 3,972 shares [3] Group 3 - For the period from January to September 2025, Aipeng Medical reported operating revenue of 252 million yuan, a year-on-year decrease of 8.41%, and a net profit attributable to the parent company of -11.4842 million yuan, a decrease of 401.64% [3] - The company has distributed a total of 113 million yuan in dividends since its A-share listing, with 16.3862 million yuan distributed over the past three years [4]

Core Viewpoint - Yinosh's stock price has experienced fluctuations, with a year-to-date increase of 28.73% but a recent decline of 9.40% over the past five trading days, indicating volatility in investor sentiment and market conditions [1]. Company Overview - Yinosh Biotechnology Co., Ltd. is located in the China (Shanghai) Pilot Free Trade Zone and was established on May 12, 2010. The company specializes in providing non-clinical research services in the biopharmaceutical sector, with 96.31% of its revenue coming from non-clinical services [1]. - The company was listed on September 3, 2024, and operates primarily in the medical biology sector, focusing on medical research outsourcing [1]. Financial Performance - As of September 30, 2025, Yinosh reported a revenue of 571 million yuan, a year-on-year decrease of 35.33%. The net profit attributable to shareholders was -14.79 million yuan, reflecting a significant decline of 111.14% compared to the previous period [2]. - The company has distributed a total of 45.11 million yuan in dividends since its A-share listing [3]. Shareholder Structure - As of September 30, 2025, the number of shareholders decreased by 9.97% to 4,849, while the average number of circulating shares per person increased by 257.28% to 18,703 shares [2]. - New institutional shareholders include Huatai-PineBridge Healthcare Mixed Fund and Huaxia Stable Growth Mixed Fund, which are now among the top ten circulating shareholders [3].

Core Viewpoint - The stock of Xinruida has experienced fluctuations, with a recent decline of 2.06% and a year-to-date increase of 2.99%, indicating volatility in its market performance [1][2]. Company Overview - Xinruida Technology Co., Ltd. was established on May 15, 2012, and went public on April 28, 2020. The company is located in Hefei Economic and Technological Development Zone, specializing in the research, design, production, sales, and technical services of new display optoelectronic systems and intelligent health light source systems [2]. - The main revenue composition of Xinruida includes display modules (88.12%), display terminals (10.24%), other (1.52%), and health intelligent light sources (0.13%) [2]. Financial Performance - For the period from January to September 2025, Xinruida achieved operating revenue of 733 million yuan, a year-on-year decrease of 4.11%. However, the net profit attributable to the parent company was 94.27 million yuan, reflecting a year-on-year increase of 25.75% [2]. - Since its A-share listing, Xinruida has distributed a total of 246 million yuan in dividends, with 167 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, Xinruida had 21,300 shareholders, a decrease of 6.86% from the previous period. The average circulating shares per person increased by 7.36% to 6,008 shares [2]. - The top ten circulating shareholders include new entrant Bodao Jiuhang Mixed A (008318), holding 443,400 shares, while several other funds have exited the top ten list [3].

Group 1 - The core viewpoint of the news is that Andavil's stock has shown fluctuations in price and trading volume, with a recent increase in share price despite a year-to-date decline [1] - As of November 19, Andavil's stock price was 17.07 CNY per share, with a market capitalization of 4.34 billion CNY and a trading volume of 39.36 million CNY [1] - The company has experienced a net inflow of main funds amounting to 1.61 million CNY, with significant buying and selling activities recorded [1] Group 2 - For the period from January to September 2025, Andavil achieved operating revenue of 447 million CNY, representing a year-on-year growth of 22.21%, while the net profit attributable to shareholders decreased by 89.28% to 567,100 CNY [2] - The number of shareholders decreased by 22.95% to 29,300, while the average number of tradable shares per person increased by 29.79% to 6,123 shares [2] Group 3 - Since its A-share listing, Andavil has distributed a total of 277 million CNY in dividends, with 61.11 million CNY distributed over the past three years [3]

Core Viewpoint - Meiside's stock price has shown a year-to-date increase of 21.84%, but has recently experienced a decline of 2.50% over the past five trading days, indicating volatility in its performance [2]. Company Overview - Meiside Chemical Co., Ltd. is located in Nanjing Economic and Technological Development Zone, Jiangsu Province, and was established on November 24, 2000. The company was listed on March 30, 2017, and specializes in the research, production, and sales of polyurethane foam stabilizers [2]. - The company's main business revenue composition includes hard foam additives (77.45%), soft foam additives (19.54%), and other (3.01%) [2]. Financial Performance - For the period from January to September 2025, Meiside achieved operating revenue of 466 million yuan, representing a year-on-year growth of 4.56%. However, the net profit attributable to shareholders decreased by 41.83% to 45.17 million yuan [2]. - Since its A-share listing, Meiside has distributed a total of 189 million yuan in dividends, with 83.33 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Meiside increased by 11.89% to 12,000, while the average circulating shares per person decreased by 10.62% to 15,272 shares [2]. - Notable institutional holdings include Nuoan Multi-Strategy Mixed A (320016) as the fourth largest circulating shareholder with 1.247 million shares, and CITIC Prudential Multi-Strategy Mixed (LOF) A (165531) as the tenth largest with 733,500 shares, both being new shareholders [3]. Market Activity - On November 19, Meiside's stock price fell by 2.05% to 12.88 yuan per share, with a trading volume of 17.38 million yuan and a turnover rate of 0.73%. The total market capitalization stands at 2.359 billion yuan [1]. - In terms of capital flow, there was a net inflow of 172,200 yuan from main funds, with large orders accounting for 5.07% of total purchases and 4.08% of total sales [1].

Group 1 - The core stock price of Beishimei increased by 2.07% on November 19, reaching 9.86 CNY per share, with a total market capitalization of 3.561 billion CNY [1] - The company experienced a stock price decline of 3.43% year-to-date, but saw a 1.75% increase over the last five trading days and a 2.28% increase over the last 20 days, while it dropped 19.51% over the last 60 days [2] - As of September 30, the number of shareholders decreased by 9.41% to 18,000, with an average of 20,046 circulating shares per person, which increased by 10.39% [2] Group 2 - Beishimei's main business includes the research, production, and sales of products such as 4-nitro intermediates, dimethenamid-p active ingredients, and dimethenamid-p formulations, with the main revenue sources being dimethenamid-p active ingredients (25.95%) and various trade pesticides [2] - For the period from January to September 2025, Beishimei achieved operating revenue of 1.11 billion CNY, representing a year-on-year growth of 14.29%, and a net profit attributable to shareholders of 31.17 million CNY, reflecting a significant year-on-year increase of 1257.94% [2] - The company has distributed a total of 62.87 million CNY in dividends since its A-share listing, with 38.52 million CNY distributed over the past three years [3]

Core Viewpoint - The stock price of SiRuPu has experienced fluctuations, with a year-to-date increase of 69.61% but a recent decline of 4.02% over the past five trading days [2] Group 1: Stock Performance - As of November 19, SiRuPu's stock price was 156.89 CNY per share, with a market capitalization of 21.62 billion CNY [1] - The stock has seen a trading volume of 1.53 billion CNY and a turnover rate of 0.72% [1] - Year-to-date, SiRuPu's stock has risen by 69.61%, with a recent 4.02% drop over the last five trading days [2] Group 2: Financial Performance - For the period from January to September 2025, SiRuPu reported a revenue of 1.531 billion CNY, representing a year-on-year growth of 80.47% [2] - The net profit attributable to shareholders for the same period was 126 million CNY, showing a significant increase of 227.64% year-on-year [2] Group 3: Shareholder Information - As of September 30, 2025, SiRuPu had 18,100 shareholders, an increase of 57.25% from the previous period [2] - The average number of circulating shares per shareholder decreased by 36.41% to 7,321 shares [2] - The company has distributed a total of 90.985 million CNY in dividends since its A-share listing, with 24.76 million CNY distributed over the last three years [3] Group 4: Institutional Holdings - As of September 30, 2025, the top ten circulating shareholders included notable funds such as Galaxy Innovation Mixed A and Wan Jia You Xuan, with varying changes in their holdings [3]